Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Certain factors like being female, having high cholesterol, using Medicaid, and previous non-biologic treatments increase the risk of multiple biologic failures in psoriasis patients.

This review discusses the potential of biologics for treating various skin disorders, highlighting positive outcomes in conditions like pityriasis rubra pilaris and lupus, while noting mixed efficacy in others like alopecia areata; it reports no new clinical results.

This review details the adverse effects and drug interactions of biologic agents used in rheumatoid disease treatment, highlighting their significant side effect profile without reporting new clinical findings.

This study systematically reviewed literature on paradoxical reactions during biologic treatments for psoriasis, identifying immune dysregulation mechanisms and diverse clinical manifestations, highlighting that mild cases often respond well to topical treatments, while severe cases may require switching to different IL-23 inhibitors.

In this overview of COPD exacerbations, it was reported that these events, often triggered by respiratory viruses, not only worsen symptoms but also increase the risk of cardiac events, highlighting the importance of early detection and prevention strategies such as vaccinations and new biologic therapies.

In this review, researchers found that TNF-α, IL-17, and JAK inhibitors show the most promise for stabilizing and resolving scarring alopecias, with IL-23 and Interferon Alpha Receptor 1 inhibitors also providing some benefits in managing these hair loss conditions.

This study reviews the efficacy and safety of advanced therapies like TNFα inhibitors and IL-17/IL-23 inhibitors for dissecting cellulitis of the scalp, finding TNFα inhibitors particularly effective for severe or refractory cases, although prospective validation is needed for early intervention benefits.

This case report details a rare instance of primary adrenal insufficiency as a manifestation of antiphospholipid syndrome, with the patient successfully managed through glucocorticoids, warfarin, and hydroxychloroquine.

This case report describes a 40-year-old man whose vitiligo and psoriasis responded favorably to ixekizumab after experiencing vitiligo onset and psoriasis relapse during adalimumab treatment.

This guideline outlines the management of systemic lupus erythematosus in adults but reports no new clinical findings.

This systematic review reports that "COVID toes" and other skin manifestations can be initial signs of COVID-19, and advises immunosuppressive therapy adjustments only for infected or at-risk patients.

This review summarizes various drug treatments for hidradenitis suppurativa, noting their effectiveness, side effects, and high recurrence rates, but reports no new clinical findings.

This systematic review reports that for patients with underlying dermatologic disorders who contracted COVID-19, most experienced mild to moderate exacerbation of their skin conditions and were managed similarly to the general population, suggesting treatment discontinuation during acute infection may prevent severe recurrence.

This review discusses therapies for skin lesions in lupus erythematosus and reports no new clinical results, focusing on defining and managing refractory disease.

This review summarizes recent research on alopecia areata, highlighting advances in targeted therapies due to improved understanding of its immunopathogenesis, though it reports no new clinical results.

In this review, the authors discuss the potential for cell therapy, such as hematopoietic stem cell transplantation and mesenchymal stromal cells, to treat severe psoriasis unresponsive to biological therapies, while highlighting the associated risks, costs, and regulatory challenges.

This article organizes and lists ongoing and completed clinical trials of novel agents for lung cancer, serving as a reference tool with no new research findings reported.

This review summarizes existing literature on the safety of commonly used dermatologic medications during pregnancy but does not present new clinical findings, aiming to assist physicians with prescribing decisions.

This study reported that dupilumab, an FDA-approved biologic, is a safe and effective first-line systemic treatment for children with moderate-to-severe atopic dermatitis, showing sustained skin improvement and itch reduction, with injection site reactions and conjunctivitis as potential side effects.

This study reviewed clinical trials and reports on cytokine-targeting biologics for alopecia areata, finding Dupilumab and Ustekinumab showed strong efficacy, while other biologics had limited success or worsened the condition. Further research is needed to optimize biologic therapies for AA.

This research notes that biologics and small molecules are effective for treating nail psoriasis and alopecia areata, albeit with precautions for adverse events, but no clinical trials have been published for their use in treating nail lichen planus and atopic dermatitis.

This review explores the efficacy and safety of treatments for dissecting cellulitis of the scalp, revealing a predominance of case reports and series, and concludes that randomized controlled trials are needed for better evidence-based therapies.

Hidradenitis Suppurativa is a chronic skin condition best treated early with surgery for better outcomes and less recurrence.

This study reviews current systemic treatments for hidradenitis suppurativa, highlighting traditional methods and new options like biological agents, and suggests that pharmacological therapies show promise, particularly for non-advanced cases, despite the disease's complex etiology involving factors such as genetics and inflammation.

This source provides medical information intended solely for licensed professionals and emphasizes that it is not a substitute for medical advice, diagnosis, or treatment decisions, which remain the responsibility of treating physicians.

This study highlights that while advances in dermatology, such as biologics and JAK inhibitors, have improved treatments for conditions like atopic dermatitis and psoriasis, challenges remain, including issues with lasting efficacy and the need for more personalized therapies.

This study synthesizes current evidence showing that menopause involves a predictable endocrine transition, while male ageing features a more variable testosterone decline, necessitating a nuanced clinical approach to diagnosis and treatment.

This review article highlights that obesity is a significant risk factor for several inflammatory skin conditions, such as psoriasis and atopic eczema, contributing to increased overall morbidity among those affected.

This review highlights the ongoing need for novel treatments for autosomal recessive congenital ichthyoses, suggesting that drug repositioning, utilizing existing medications or biologics, could provide more affordable and effective options for managing this lifelong skin condition.

This article discusses the role of hyperarousal and brain activity in insomnia and its potential link to sleep disturbances in depression, but it reports no new empirical findings.